Welcome to our dedicated page for Vyome Holdings SEC filings (Ticker: HIND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vyome Holdings, Inc. filings document the public-company record of a Nasdaq-listed clinical-stage biopharmaceutical issuer. Its disclosures cover operating and financial results, Regulation FD presentation materials, material definitive agreements, clinical and regulatory program information, and capital-structure matters involving its common stock.
Proxy statements and Form 8-K reports describe shareholder votes, director elections, equity incentive plan matters, auditor ratification, executive-compensation advisory votes, and charter amendments, including a reduction in authorized common shares. The filings also provide formal records of governance actions and risk-related disclosure categories relevant to Vyome’s pharmaceutical and biotechnology operations.
Vyome Holdings (HIND) reported results of its 2025 Annual Meeting of Stockholders. A quorum of 4,258,856 shares, representing 77.52% of shares outstanding and eligible to vote, was present in person or by proxy.
Stockholders elected Krishna K. Gupta, Shiladitya Sengupta and Stash Pomichter as Class I directors to serve until the 2028 annual meeting. The 2025 Equity Incentive Plan was approved with 3,766,413 votes for, 184,403 against, and 6,600 abstentions, with 301,440 broker non-votes. Stockholders ratified Kreit & Chiu CPA LLP as independent auditor for the fiscal year ending December 31, 2025 with 4,248,216 votes for, 10,081 against, and 559 abstentions.
On a non-binding advisory basis, compensation of named executive officers was approved with 3,945,592 votes for, 11,052 against, 772 abstentions, and 301,440 broker non-votes.
Vyome Holdings, Inc. filed a Definitive Proxy Statement (DEF 14A) describing items for its annual meeting, including four proposals: the election of three Class I directors, approval of an equity Plan, ratification of the auditor, and an advisory vote on executive compensation. The filing lists nominees Krishna K. Gupta, Shiladitya Sengupta, and Stash Pomichter for three-year terms and profiles key executives including CEO Venkat Nelabhotla and CFO Robert Dickey.
The proxy explains voting mechanics for shares held in street name, noting that brokers cannot vote on certain non-routine proposals without instructions, which may lead to broker non-votes. It discloses related-party consulting payments (e.g., Dr. Sengupta: $100,000 per annum and $151,939 in VTI stock awards for 2024), director compensation retainers, stockholder proposal deadline of June 30, 2026, and prior material weaknesses in internal control reported in the Company’s Form 10-K for fiscal years 2023 and 2022.
Vyome Holdings, Inc. (HIND) announced it acquired Oculo, Inc. On September 29, 2025, the company reported the purchase of Oculo, an AI startup launched at the Massachusetts Institute of Technology. The announcement was made under Other Events, with a press release furnished as Exhibit 99.1.
This move signals Vyome’s interest in artificial intelligence capabilities originating from MIT’s ecosystem. Additional details are provided in the attached press release referenced in the filing.
Vyome Holdings Form 4: This Form 4 reports that Venkat Nelabhotla, President, CEO and a director, received 7 shares of Vyome Holdings common stock as a result of a merger on 08/15/2025. Under the Merger Agreement, each 5,000 shares of Vyome Therapeutics common stock converted into 1 share of Vyome Holdings common stock. The reporting person exchanged 35,000 Vyome Therapeutics shares and received 7 Vyome Holdings shares. The Form 4 was filed as a single reporting person and is signed on 09/22/2025.
John M. Tincoff III filed an initial Form 3 reporting his relationship to Vyome Holdings, Inc. (ticker shown in the filing as HIND) as a Director. The event date is 08/15/2025. The filing states no securities are beneficially owned by the reporting person. The form is signed and dated 09/18/2025.